ALLO-GLUE
Live / Applied — Third extension granted (statement of use) (as of 20 Jun 2025)
What this means for you
Not registered yet, but its 13 Dec 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97716240
- Mark type
- Stylized text
- Filed
- 13 Dec 2022
- Published for opposition
- 31 Oct 2023
- Attorney of record
- Rachelle A. Dubow, Esq.
Goods and services
- Class 001 — Chemicals: Diagnostic and chemical reagents for scientific and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical ingredients for use in the manufacture of small molecule pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases
- Class 005 — Pharmaceuticals: Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorders; Biochemical preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases
- Class 042 — Scientific and technological services: Development of new technology for others in the field of biotechnology; scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; biotechnical research; technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology and pharmaceutical research and development; consulting services in the field of laboratory testing for scientific purposes in the field of pharmaceuticals and biotechnology; consulting services in the field of research and development of new products relating to diagnosis of diseases; consulting services in the field of pharmacogenetics; research and development of pharmaceuticals for others; scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism
Owner
- Orionis Biosciences Inc., Waltham, MA, US
- Orionis Biosciences Inc., Waltham, MA, US
Prosecution history
- 16 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
- 16 Dec 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 16 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Jun 2025 — SOU EXTENSION 3 GRANTED
- 20 Jun 2025 — SOU EXTENSION 3 FILED
- 20 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Dec 2024 — SOU EXTENSION 2 GRANTED
- 23 Dec 2024 — SOU EXTENSION 2 FILED
- 23 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jun 2024 — SOU EXTENSION 1 GRANTED
- 11 Jun 2024 — SOU EXTENSION 1 FILED
- 11 Jun 2024 — SOU TEAS EXTENSION RECEIVED